BBLG
Bone Biologics CorpPrice
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- E Jul 8 Offering: Bone Biologics Announces up to $9.0 Million Private Placem…
- R Jul 8 Bone Biologics (BBLG) announced a private placement raising $3.0M th…
- R Jul 17 Bone Biologics filed an S-3 registration statement to register 6,464…
- R Jul 27 Bone Biologics' S-3 shelf registration (File No. 333-297550) became…
- X Aug 14 Short interest jumps 646.3% to 156.6K
- X Aug 31 Short interest falls 76.4% to 37.0K
- X Sep 30 Short interest jumps 38.1% to 49.5K
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q1 2026: 0 added (0 new), 1 trimmed or exited.
- TrendDOWNTREND
28% below its 50-day average. New closing low $0.3680 on Oct 27.
- SocialQUIET
Crowd 64° (warm) this week from 3 mentions: 2 bullish, 0 bearish. No setup call. Excludes 1 subscriber-only day.
Who's buying
13F· Q1 2026| Fund | Move | Value |
|---|---|---|
| UBS Group AG | NEAR_EXIT | $62.00 |
| UBS Group AG | DOUBLED | $2.8K |
| UBS Group AG | TRIM | $184.00 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | $39.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Price is below the lowest target. Median implies +3215%.Targets as of Oct 27, 2026.
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Sep 28, 2026 | Meikle Phillip Terry II Director | AWARD | 113,896 sh |
| Sep 28, 2026 | Angle Siddhesh Rajendra Director | AWARD | 113,896 sh |
| Sep 28, 2026 | Stroever Bruce Director | AWARD | 113,896 sh |
| Sep 28, 2026 | Gagnon Robert E. Director | AWARD | 113,896 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | -$1.23 | -$1.23–-$1.23 | -5.1% | $0.00 |
| Next FY | -$0.67 | -$0.67–-$0.67 | -4.7% | $0.00 |
Short side
FINRA· Oct 15, 2026SecBot reports
5 filings · 1 press release · 0 bullish · 2 bearish · 3 neutral- NEUTRAL 25-NSEOct 13, 2026
Nasdaq filed a Form 25-NSE to remove Bone Biologics Corp's warrants from listing and registration…
Monitor Bone Biologics Corp's common stock for any subsequent delisting risk or corporate events, but this filing is a routine warrant removal with no direct read-through to the equity.
- BEARISH EFFECTJul 27, 2026
Bone Biologics' S-3 shelf registration (File No. 333-297550) became effective on July 24, 2026…
The shelf effectiveness removes the last barrier to selling stockholder sales. Expect immediate downward pressure as Armistice Capital can now sell into the market. Monitor for a Form 424B5…
- NEUTRAL DEFA14AJul 20, 2026
Bone Biologics postponed its 2026 annual meeting from August 11 to September 28, 2026, citing the…
Monitor the upcoming definitive proxy statement for the nature of the additional proposal—this could signal a governance change, equity issuance, or strategic transaction. The extended timeline…
- BEARISH S-3Jul 17, 2026
Bone Biologics filed an S-3 registration statement to register 6,464,792 shares of common stock…
The massive overhang from the S-3 resale registration will likely crush the stock price. Expect heavy selling pressure as Armistice Capital and other selling stockholders look to exit. The stock is…
All BBLG filing & press-release reports (6)
- 25-NSE reportOct 13, 2026
- EFFECT reportJul 27, 2026
- DEFA14A reportJul 20, 2026
- S-3 reportJul 17, 2026
- PRESS-RELEASE reportJul 8, 2026
- DEFA14A reportJul 2, 2026